SANTHERA N/ CH1276028821 /
- - | Chg. - | Volume | Bid- | Ask- | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
-EUR | - | 0 Turnover: 0.00 |
-Bid Size: - | -Ask Size: - | 124.56 mill.EUR | - | - |
GlobeNewswire
8/13
Santhera Closes Financings and Secures Funds to Reach Break-Even Expected in 2026
GlobeNewswire
7/31
Santhera Appoints Dr. Oliver P. Kronenberg as Chief Legal Officer and Company Secretary
GlobeNewswire
6/18
Santhera’s Shareholders Approve all Board Proposals at Today’s Annual General Meeting
GlobeNewswire
6/18
Santhera Secures up to CHF 69 million in Royalty and Debt Financing to Fund Operations to Cash Flow ...
GlobeNewswire
6/10
Santhera Announces Launch of Early Access Program in China for AGAMREE® by its Partner Sperogenix
GlobeNewswire
4/25
Santhera Announces Preliminary Unaudited 2023 Annual Results and Provides Corporate Update Ahead of ...
GlobeNewswire
3/27
Santhera Announces NDA for Vamorolone in Duchenne Muscular Dystrophy Accepted and Granted Priority R...
GlobeNewswire
3/14
Santhera’s Partner Catalyst Pharmaceuticals Launches AGAMREE® (Vamorolone) in the United States
GlobeNewswire
3/13
Catalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U.S. for the Treatment...
GlobeNewswire
2/29
Catalyst Pharmaceuticals Reports Strong Fourth Quarter and Full Year 2023 Financial Results and Prov...
GlobeNewswire
2/21
Catalyst Pharmaceuticals Announces Publication of Santhera Pharmaceutical’s VISION-DMD Vamorolone (A...
GlobeNewswire
2/14
Santhera Announces Publication of Efficacy, Safety and Tolerability Data with Vamorolone (AGAMREE®) ...
GlobeNewswire
2/13
Onconetix Announces Appointment of Seasoned Biotech Executives Dr. Ajit Singh and Dr. Thomas Meier t...
GlobeNewswire
1/15
Santhera Launches AGAMREE® (Vamorolone) in Germany as First Market for the Treatment of Duchenne Mus...
GlobeNewswire
1/12
Santhera Receives Approval for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy ...
GlobeNewswire
12/18/2023
Santhera’s AGAMREE® (Vamorolone) Approved in the European Union for the Treatment of Duchenne Muscul...
GlobeNewswire
12/7/2023
Santhera Appoints Executive Committee Members as it Transitions into Commercial Stage
GlobeNewswire
10/27/2023
Santhera Receives U.S. FDA Approval of AGAMREE® (vamorolone) for the Treatment of Duchenne Muscular ...
GlobeNewswire
10/26/2023
Catalyst Pharmaceuticals Reports FDA Approval of AGAMREE® (vamorolone) for Duchenne Muscular Dystrop...
GlobeNewswire
10/16/2023
Patrick J. McEnany, Chairman and CEO of Catalyst Pharmaceuticals, Receives Prestigious 2023 Lifetime...
GlobeNewswire
10/13/2023
Santhera Receives Positive CHMP Opinion Recommending Approval of AGAMREE® (vamorolone) for the Treat...
GlobeNewswire
9/7/2023
Santhera Announces Half-Year 2023 Financial Results and Provides Corporate Update